



Tesofensine is a novel reuptake inhibitor that affects norepinephrine (NE), serotonin (5-HT) and dopamine (DA) function. All of these neurotransmitters play a role in hunger, appetite and weight loss. As such, Tesofensine acts primarily as an appetite suppressant. However, it has been also shown to increase resting energy expenditure which assists in more rapid weight loss.

In clinical trials, patients taking Tesofensine reported a decreased craving for sweet, fatty and salty foods. Cardiometabolic markers of health were also improved in patients taking Tesofensine. Also reported were improvements in quality of life, increases in physical activity and improvements in self-esteem.

In addition, patients treated with Tesofensine displayed the following results:

- Reduction in appetite sensations within a period of 14 days, with those being treated reporting a greater level of satiety and less desire to eat.
- Significant increase in fat oxidation and reduction in fat tissue. 24-hour fat oxidation increased by 15% and there was a reduction in protein oxidation. Scanning was able to provide confirmation of a statistically significant reduction in fat tissue compared with the placebo control group.
- Improved levels of insulin sensitivity were noted, leading to a higher metabolism of glucose, making this medication potentially suitable for patients at risk from type II diabetes.
- After 14 days, a significant increase in energy expenditure at rest was observed compared with the placebo control group. This increase was directly linked to Tesofensine and any external factors were excluded as possible causes.

